Our in vitro effects recommend that EAM-2201 should be examined with regards to probable in vivo pharmacokinetic drug–drug interactions because of time-dependent inhibition of CYP2C8, CYP2C9, CYP2C19 and CYP3A4 functions and aggressive inhibition of UGT1A3 action. That is a preview of subscription material, log in via an institution to check https://carolec949kzn1.dailyblogzz.com/profile